
Lantern Pharma Inc. Common Stock
LTRN
LTRN: Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets.
moreShow LTRN Financials
Recent trades of LTRN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LTRN's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Increasing cancer patient survival time by administration of dithio-containing compounds Oct. 18, 2022
Federal grants, loans, and purchases
Followers on LTRN's company Twitter account
Number of mentions of LTRN in WallStreetBets Daily Discussion
Recent insights relating to LTRN
Recent picks made for LTRN stock on CNBC
ETFs with the largest estimated holdings in LTRN
Flights by private jets registered to LTRN